Breaking News

ProBioGen, Heidelberg Pharma Ink ATAC Agreement

ProBioGen is conducting cell line development, process development and GMP manufacturing of the mAb intermediates of Heidelberg’s ATAC molecules for cancer.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen AG, a service and technology provider for complex therapeutic antibodies and glycoproteins, signed a Master Service Agreement with Heidelberg Pharma for the antibodies used in two of its pipeline Antibody Targeted Amanitin Conjugate (ATAC) molecules. Under the agreement, ProBioGen is conducting the full service package from cell line development using its CHO.RiGHT cell line expression platform and DirectedLuck Transposase system for the generation of high titer producer clones, thr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters